{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T12:18:17Z","timestamp":1784290697575,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T00:00:00Z","timestamp":1590537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T00:00:00Z","timestamp":1590537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Anaplastic lymphoma kinase (ALK) rearrangement is a predictive factor of response to ALK inhibitors in non small cell lung cancer (NSCLC). The prevalence of ALK rearrangements is well known in Whites and Asians. However, data identifying the frequency of this rearrangement in Moroccan and North African population are lacking. The objective of this study is to report the frequency of ALK rearrangement in a group of Moroccan patients with NSCLC.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>A retrospective study was performed enrolling 120 Moroccan patients with NSCLC whose biopsy samples were tested for ALK rearrangement in order to identify the frequency of ALK rearrangement and its potential association with selected variables. The ALK testing was established using fluorescent in situ hybridization (FISH) or immunohistochemistry (IHC).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The frequency of ALK rearrangement was 4.2% (5\/120). All positive cases were males with advanced adenocarcinoma. ALK rearrangements prevalence was significantly higher in older patients.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The frequency of ALK rearrangements among the Moroccan population tends to correlate with the average frequency reported worldwide, with some specific features. Further prospective studies with larger patients\u2019 numbers are needed to verify these findings.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12885-020-06973-4","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T11:03:40Z","timestamp":1590577420000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Frequency of anaplastic lymphoma kinase rearrangements in Moroccan patients with non small cell lung cancer: a multi-institutional national retrospective study"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8037-3610","authenticated-orcid":false,"given":"Hind","family":"El yacoubi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Lemine","family":"Sow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fouad","family":"Kettani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamia","family":"Gamra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"Mestari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamia","family":"Jabri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Elghissassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Errihani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,27]]},"reference":[{"issue":"6","key":"6973_CR1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"6973_CR2","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","volume":"448","author":"M Soda","year":"2007","unstructured":"Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561\u20136.","journal-title":"Nature"},{"issue":"4","key":"6973_CR3","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/1759-7714.12613","volume":"9","author":"D Xue","year":"2018","unstructured":"Xue D, Yun S, Hai-Feng Q, et al. ALK-rearrangement in non-small-cell lung cancer (NSCLC). Thorac Cancer. 2018;9(4):423\u201330.","journal-title":"Thorac Cancer"},{"key":"6973_CR4","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1200\/JCO.2017.77.4794","volume":"36","author":"BJ Solomon","year":"2018","unstructured":"Solomon BJ, Kim DW, Wu YL, et al. Final overall survival analysis from a study comparing first-line Crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung Cancer. J Clin Oncol. 2018;36:2251.","journal-title":"J Clin Oncol"},{"issue":"23","key":"6973_CR5","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","volume":"371","author":"BJ Solomon","year":"2014","unstructured":"Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014 Dec 4;371(23):2167\u201377.","journal-title":"N Engl J Med"},{"issue":"6","key":"6973_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0100866","volume":"9","author":"L Fan","year":"2014","unstructured":"Fan L, Feng Y, Wan H, et al. Clinicopathological and demographical characteristics of non-small cell lung cancer patients with ALK rearrangements: a systematic review and meta-analysis. PLoS One. 2014;9(6):e100866.","journal-title":"PLoS One"},{"key":"6973_CR7","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","volume":"27","author":"AT Shaw","year":"2009","unstructured":"Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27:4247.","journal-title":"J Clin Oncol"},{"key":"6973_CR8","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.lungcan.2016.10.010","volume":"102","author":"AM Chapman","year":"2016","unstructured":"Chapman AM, Sun KY, Ruestow P, et al. Lung cancer mutation profile of EGFR, ALK, and KRAS: meta-analysis and comparison of never and ever smokers. Lung Cancer. 2016;102:122\u201334.","journal-title":"Lung Cancer"},{"key":"6973_CR9","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1093\/annonc\/mds626","volume":"24","author":"JX Zhou","year":"2013","unstructured":"Zhou JX, Yang H, Deng Q, et al. Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages. Ann Oncol. 2013;24:1319\u201325.","journal-title":"Ann Oncol"},{"issue":"20","key":"6973_CR10","doi-asserted-by":"publisher","first-page":"5682","DOI":"10.1158\/1078-0432.CCR-11-2947","volume":"18","author":"M Soda","year":"2012","unstructured":"Soda M, Isobe K, Inoue A, et al. A prospective PCR-based screening for the EML4-ALK oncogene in non-small cell lung Cancer. Clin Cancer Res. 2012;18(20):5682\u20139.","journal-title":"Clin Cancer Res"},{"key":"6973_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3346\/jkms.2012.27.2.228","volume":"27","author":"G Jin","year":"2012","unstructured":"Jin G, Jeon HS, Lee EB, et al. EML4-ALK fusion gene in Korean non-small cell lung cancer. J Korean Med Sci. 2012;27:228\u201330.","journal-title":"J Korean Med Sci"},{"issue":"1","key":"6973_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052261","volume":"8","author":"P Martinez","year":"2013","unstructured":"Martinez P, Hernandez-Losa J, Montero MA, et al. Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients. PLoS One. 2013;8(1):e52261.","journal-title":"PLoS One"},{"issue":"1","key":"6973_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.lungcan.2013.07.013","volume":"82","author":"N Yamaguchi","year":"2013","unstructured":"Yamaguchi N, Vanderlaan PA, Folch E, et al. Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States based academic medical practice. Lung Cancer. 2013 Oct;82(1):31\u20137.","journal-title":"Lung Cancer"},{"issue":"2","key":"6973_CR14","doi-asserted-by":"publisher","first-page":"80","DOI":"10.4103\/0019-509X.117007","volume":"50","author":"SS Desai","year":"2013","unstructured":"Desai SS, Shah AS, Prabhash K, Jambhekar NA. A year of anaplastic large cell kinase testing for lung carcinoma: pathological and technical perspectives. Indian J Cancer. 2013;50(2):80\u20136.","journal-title":"Indian J Cancer"},{"issue":"4","key":"6973_CR15","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1080\/15321819.2017.1319860","volume":"38","author":"AT Arfaoui","year":"2017","unstructured":"Arfaoui AT, Blel A, Aloui R, et al. ALK protein expression in pulmonary adenocarcinoma of Tunisian patients. J Immunoassay Immunochem. 2017;38(4):411\u20139.","journal-title":"J Immunoassay Immunochem"},{"issue":"3","key":"6973_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.retram.2018.02.004","volume":"66","author":"A Arfaoui Toumi","year":"2018","unstructured":"Arfaoui Toumi A, Blel A, Aloui R, et al. Assessment of EGFR mutation status in Tunisian patients with pulmonary adenocarcinoma. Curr Res Transl Med. 2018;66(3):65\u201370.","journal-title":"Curr Res Transl Med"},{"key":"6973_CR17","doi-asserted-by":"publisher","first-page":"4273","DOI":"10.1158\/1078-0432.CCR-13-0318","volume":"19","author":"JF Gainor","year":"2013","unstructured":"Gainor JF, Varghese AM, Ou SH, et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res. 2013;19:4273\u201381.","journal-title":"Clin Cancer Res"},{"key":"6973_CR18","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/1476-4598-9-188","volume":"9","author":"X Zhang","year":"2010","unstructured":"Zhang X, Zhang S, Yang X, et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer. 2010;9:188.","journal-title":"Mol Cancer"},{"key":"6973_CR19","doi-asserted-by":"publisher","first-page":"25046","DOI":"10.18632\/oncotarget.15337","volume":"8","author":"W Hu","year":"2017","unstructured":"Hu W, Liu Y, Chen J. Concurrent gene alterations with EGFR mutation and treatment efficacy of EGFR-TKIs in Chinese patients with non-small cell lung cancer. Oncotarget. 2017;8:25046\u201354.","journal-title":"Oncotarget"},{"key":"6973_CR20","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jtho.2016.12.003","volume":"12","author":"S Schmid","year":"2017","unstructured":"Schmid S, Gautschi O, Rothschild S, et al. Clinical outcome of ALK-positive non-small cell lung cancer (NSCLC) patients with de novo EGFR or KRAS co-mutations receiving tyrosine kinase inhibitors (TKIs). J Thorac Oncol. 2017;12:681\u20138.","journal-title":"J Thorac Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-06973-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-06973-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-06973-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T23:20:25Z","timestamp":1622071225000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-06973-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,27]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["6973"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-06973-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,27]]},"assertion":[{"value":"6 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The ethics committee approval was not necessary for this study, since all ALK tests were part of the routine diagnostic procedure and all patient and tumor characteristics were collected anonymously.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"479"}}